Redeye retains its positive view despite lowering its Base Case and forecasts. We consider the Q2 report a mixed bag. The most important metric, ARR growth, was strong and slightly better than anticipated, while OPEX was substantially higher than we expected, hurting profitability.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vertiseit - Solid Top Line While High OPEX Hurt Profitability

© Modular Finance, source Nordic Press Releases